Compare FCFS & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCFS | TGTX |
|---|---|---|
| Founded | 1988 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.5B |
| IPO Year | 1996 | 2008 |
| Metric | FCFS | TGTX |
|---|---|---|
| Price | $219.88 | $56.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $210.67 | $49.80 |
| AVG Volume (30 Days) | 407.9K | ★ 1.8M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | 29.49 | ★ 1746.67 |
| EPS | ★ 4.56 | 0.17 |
| Revenue | ★ $3,661,043,000.00 | $2,785,000.00 |
| Revenue This Year | $16.20 | $49.08 |
| Revenue Next Year | $8.35 | $26.69 |
| P/E Ratio | ★ $48.02 | $332.18 |
| Revenue Growth | ★ 8.04 | N/A |
| 52 Week Low | $145.42 | $26.76 |
| 52 Week High | $238.93 | $59.30 |
| Indicator | FCFS | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 60.38 |
| Support Level | $204.76 | $51.51 |
| Resistance Level | $231.42 | $58.12 |
| Average True Range (ATR) | 6.42 | 2.26 |
| MACD | -0.79 | 0.06 |
| Stochastic Oscillator | 50.50 | 81.68 |
FirstCash Holdings Inc is an operator of pawn stores in the U.S., Latin America and the U.K. The company's primary line of business is the operation of retail pawn stores, also known as pawnshops. It also operates a retail POS payment solutions business. Its two business lines are organized into four reportable segments: The U.S. pawn segment consists of pawn operations in some of U.S. states and the District of Columbia; The Latin America pawn segment consists of pawn operations in Mexico, Guatemala, El Salvador and Colombia; The U.K. pawn segment consists of pawn operations in England, Scotland and Wales; and The retail POS payment solutions segment consists of the operations of American First Finance, LLC, which offers products in the U.S.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.